ライフサイエンスコーパス: flow-mediated dilation

1 25, p = 0.03) were independent predictors of flow-mediated dilation.

2 r reactivity was measured by brachial artery flow-mediated dilation.

3 cardiac effects of EECP on peripheral artery flow-mediated dilation.

4 ein, respectively, along with artery luminal flow-mediated dilation.

5 Vascular reactivity was measured by flow-mediated dilation.

6 raditional CMV risk were not associated with flow-mediated dilation.

7 ia (20 min) and reperfusion, and measured by flow-mediated dilation.

8 affeine (200 mg) had no short-term effect on flow-mediated dilation.

9 assessed by measuring arterial stiffness and flow-mediated dilation.

10 ular endothelial function by brachial artery flow-mediated dilation.

11 sical functioning score, and brachial artery flow-mediated dilation.

12 found between diesel exhaust inhalation and flow-mediated dilation.

13 ial function in the brachial artery by using flow-mediated dilation.

14 ence of a threshold for the effect of SHS on flow-mediated dilation.

15 rease in endothelial function as measured by flow-mediated dilation.

16 n ms(2) [95% CI, -0.5 to 0.1]; P<0.001), and flow-mediated dilation (0.3% [95% CI, -0.3 to 1.0] versu

17 g; P < 0.001) lower, the treatment effect on flow-mediated dilation [-0.62% (95% CI: -1.48%, 0.24%)]

18 ith HFpEF had more severe PED than controls: flow-mediated dilation 1.95% (-0.81 to 4.92) versus 5.02

19 inol associated with a trend toward improved flow-mediated dilation (+1.4% [3.9%] versus -0.7% [4.1%]

20 Brachial artery flow-mediated dilation, 24-hour urinary levels of 8-isop

21 endothelial function: lower coronary artery flow-mediated dilation (-3.1+/-15.5 versus 15.9+/-17.3%;

22 (93 +/- 67% vs. 145 +/- 106%, p = 0.006) and flow-mediated dilation (4.2 +/- 1.8% vs. 5.4 +/- 1.7%, p

23 2 before ischemia prevented this decrease in flow-mediated dilation (5.9 +/- 0.7% vs. 5.2 +/- 0.5%, p

24 anakinra, there was a greater improvement of flow-mediated dilation (57+/-4% versus 47+/-5%), coronar

25 associated with a significant improvement in flow-mediated dilation (6.6+/-4.4% vs. 11.0+/-6.3%; P =

26 us 15.9+/-17.3%; P<0.01) and brachial artery flow-mediated dilation (6.7+/-14.7 versus 26.4+/-15.2%;

27 Placebo treatment produced no change in flow-mediated dilation (7.0+/-3.9% vs. 7.2+/-3.7%), wher

28 study, we observed improved brachial artery flow-mediated dilation (7.7 +/- 2.9% to 8.7 +/- 3.1%, P

29 is associated with impaired brachial artery flow-mediated dilation, a surrogate of endothelial dysfu

30 on, as evidenced by impaired brachial artery flow-mediated dilation, abnormal cerebral blood flow, sk

31 CO 3 did result in a significant increase in flow-mediated dilation after 1 month; however, this effe

32 as change in maximal percent brachial artery flow-mediated dilation after exposure.

33 dysfunction (as evaluated by brachial artery flow-mediated dilation) after 8 hours.

34 ate variability, baroreflex sensitivity, and flow-mediated dilation, along with 24-hour urinary catec

35 with baseline diameter and the percentage of flow-mediated dilation, although these associations were

36 Secondary endpoints were change in flow-mediated dilation and augmentation index.

37 No correlation was found between changes in flow-mediated dilation and changes in low-density lipopr

38 dest unadjusted inverse correlations between flow-mediated dilation and CRP, IL-6, and sICAM-1 (P<0.0

39 Baseline flow-mediated dilation and endothelial progenitor cell l

40 has a beneficial effect on peripheral artery flow-mediated dilation and endothelial-derived vasoactiv

41 Indeed, both flow-mediated dilation and endothelium-dependent vasodil

42 continuous positive airway pressure therapy, flow-mediated dilation and expression of eNOS and phosph

43 ed to endothelial phenotype, as reflected by flow-mediated dilation and expression of P-selectin.

44 Women with hot flashes had reduced flow-mediated dilation and greater aortic calcification.

45 at women with hot flashes would show reduced flow-mediated dilation and greater coronary artery and a

46 ong inverse relation between brachial artery flow-mediated dilation and increasing quartile of serum

47 zyme-linked immunoassay, and brachial artery flow-mediated dilation and nitroglycerin-mediated dilati

48 influences brachial reactivity, we examined flow-mediated dilation and nitroglycerin-mediated dilati

49 as a significant inverse correlation between flow-mediated dilation and pulmonary vascular resistance

50 studied endothelium-dependent (posthyperemia flow-mediated dilation) and -independent (nitroglycerin)

51 dothelial function of conduit (radial artery flow-mediated dilation) and resistance vessels (blood fl

52 ght coronary wall thickness, coronary artery flow-mediated dilation, and brachial artery flow-mediate

53 dilatory responses to acetylcholine, loss of flow-mediated dilation, and increased systolic and diast

54 telomerase activity modulates microvascular flow-mediated dilation, and loss of telomerase activity

55 ial function was assessed as brachial artery flow-mediated dilation, and microvascular function was a

56 by forearm venous occlusion plethysmography, flow-mediated dilation, and pulse wave analysis.

57 eadmill walking performance, brachial artery flow-mediated dilation, and quality of life but did not

58 tion, normalized altered signaling pathways, flow-mediated dilation, and the increased oxidative stre

59 reatments in daytime ambulatory systolic BP, flow-mediated dilation, and total cholesterol/HDL choles

60 reased endothelium-dependent brachial artery flow-mediated dilation at 16 weeks, whereas placebo did

61 nge in endothelium-dependent brachial artery flow-mediated dilation at 16 weeks.

62 ase in blood flow (r=0.50, P=0.001) and with flow-mediated dilation at baseline (r=0.50, P=0.001).

63 inutes of forearm occlusion (Brachial Artery Flow Mediated Dilation = BAFMD) and a cold pressor test

64 Endothelial function was assessed by flow-mediated dilation before and after IR (20 minutes o

65 we measured ulnar artery flow, diameter, and flow-mediated dilation before and after removal of the a

66 vels, ROCK activity, C-reactive protein, and flow-mediated dilation before and after treatment.

67 ificant associations between hot flashes and flow-mediated dilation (beta=-0.97; SE, 0.44; P=0.03) an

68 hes were associated with significantly lower flow-mediated dilation (beta=-1.01; SE, 0.41; P=0.01) an

69 The difference in flow-mediated dilation between the top and bottom fifths

70 strong inverse correlation between ADMA and flow-mediated dilation but only in the group of women wh

71 ations in acetylcholine-mediated dilation or flow-mediated dilation but were hypertensive.

72 Salsalate increased brachial artery flow-mediated dilation by 74% (from 4.0+/-0.4% to 6.6+/-

73 Low birth weight was associated with reduced flow-mediated dilation (coefficient=0.18 kg(-1), 95% CI

74 lipoprotein cholesterol, and brachial artery flow-mediated dilation compared with lean subjects (p <

75 When a flow-mediated dilation cutpoint of 8.1% was used, endoth

76 Peak flow-mediated dilation decreased by 43% after ischemia-r

77 Brachial artery flow-mediated dilation, digital pulse amplitude tonometr

78 Cardiovascular outcomes included flow mediated dilation, distensibility coefficient, puls

79 1), nor was there an effect of L-arginine on flow-mediated dilation during hyperemia (3.8 +/- 3.0% vs

80 usion of vitamin C increased brachial artery flow-mediated dilation during placebo (P<0.001) but not

81 luded a brachial artery ultrasound to assess flow-mediated dilation, electron beam tomography to asse

82 During each trial, brachial artery flow mediated dilation (FMD) was used to assess endothel

83 adults, measured as fasting brachial artery flow--mediated dilation (FMD).

84 exercise training on radial artery L-FMC and flow-mediated dilation (FMD) after transradial catheteri

85 Flow-mediated dilation (FMD) after upper arm occlusion w

86 and short-term air pollutant exposures with flow-mediated dilation (FMD) and baseline arterial diame

87 he association between brachial NO-dependent flow-mediated dilation (FMD) and cardiovascular disease

88 trasound measurements of the brachial artery flow-mediated dilation (FMD) and carotid artery intima-m

89 Participants' arterial flow-mediated dilation (FMD) and carotid-femoral pulse w

90 ry end points were change in brachial artery flow-mediated dilation (FMD) and change in aortic pulse

91 control subjects we examined brachial artery flow-mediated dilation (FMD) and circulating micropartic

92 Endothelium-dependent, flow-mediated dilation (FMD) and endothelium-independent

93 We examined brachial artery flow-mediated dilation (FMD) and flow-mediated slowing (

94 Brachial artery flow-mediated dilation (FMD) and nitroglycerin-mediated

95 the impact of blueberry flavonoid intake on flow-mediated dilation (FMD) and polyphenol absorption a

96 Flow-mediated dilation (FMD) and reactive hyperemia (RH)

97 Non-DAUs- (n = 15) showed improved brachial flow-mediated dilation (FMD) and reduced circulating IL-

98 The relationship between impaired brachial flow-mediated dilation (FMD) and subsequent clinical car

99 stimate and compare endothelial function via flow-mediated dilation (FMD) assessment in periodontal h

100 ma nicotine, exhaled CO, and brachial artery flow-mediated dilation (FMD) before and after charcoal-h

101 nship between vascular wall shear stress and flow-mediated dilation (FMD) in humans, and 2) to invest

102 cy of ERa was associated with a reduction in flow-mediated dilation (FMD) in one man.

103 week 24 within-arm change in brachial artery flow-mediated dilation (FMD) in participants with comple

104 tors, we measured coronary vasomotion during flow-mediated dilation (FMD) in response to adenosine, c

105 s assessed by vascular ultrasound to measure flow-mediated dilation (FMD) in response to forearm reac

106 Endothelial function was assessed by flow-mediated dilation (FMD) in the brachial artery in r

107 Flow-mediated dilation (FMD) increased significantly aft

108 Flow-mediated dilation (FMD) of coronary arterioles was

109 Flow-mediated dilation (FMD) of the brachial artery and

110 pulmonary endothelial function, assessed by flow-mediated dilation (FMD) of the brachial artery and

111 Endothelial function was assessed by flow-mediated dilation (FMD) of the brachial artery pree

112 e, estimated glomerular filtration rate, and flow-mediated dilation (FMD) of the brachial artery were

113 ) diet for 6 months on endothelium-dependent flow-mediated dilation (FMD) of the brachial artery were

114 Flow-mediated dilation (FMD) of the brachial artery, a m

115 ging (MRI), assessed endothelial function by flow-mediated dilation (FMD) of the brachial artery, and

116 Changes in endothelial function, measured as flow-mediated dilation (FMD) of the brachial artery, has

117 e diets on endothelial function, assessed by flow-mediated dilation (FMD) of the brachial artery.

118 determine whether smoking cessation improves flow-mediated dilation (FMD) of the brachial artery.

119 n was examined by measuring ischemia-induced flow-mediated dilation (FMD) of the brachial artery.

120 Although brachial artery flow-mediated dilation (FMD) predicts recurrent cardiova

121 aim was to determine reproducibility of the flow-mediated dilation (FMD) response profile, and discr

122 Meta-analysis of flow-mediated dilation (FMD) studies indicate 13% lower

123 The flow-mediated dilation (FMD) test is commonly utilized a

124 Endothelial function was assessed as flow-mediated dilation (FMD) using ultrasound.

125 oring (ABPM), pre-ejection period (PEP), and flow-mediated dilation (FMD) values.

126 al artery ultrasound, endothelium-dependent, flow-mediated dilation (FMD) was assessed in patients wi

127 Brachial artery flow-mediated dilation (FMD) was determined by B-mode ul

128 ted from a forearm vein, and brachial artery flow-mediated dilation (FMD) was measured before and 24

129 ed by mathematical modeling; brachial artery flow-mediated dilation (FMD) was measured before and aft

130 Preoperative endothelium-dependent flow-mediated dilation (FMD) was significantly lower in

131 e (CFR), total arterial compliance (TAC) and flow-mediated dilation (FMD) were assessed in the chroni

132 Flow-mediated dilation (FMD), although the established t

133 s by CMR, changes in endothelial function by flow-mediated dilation (FMD), and arterial stiffness by

134 files, brachial artery endothelial-dependent flow-mediated dilation (FMD), and flow-independent nitro

135 The primary outcome was a change in flow-mediated dilation (FMD), and secondary outcomes wer

136 c pulse wave velocity (PWV), brachial artery flow-mediated dilation (FMD), and serum inflammatory mar

137 Flow-mediated dilation (FMD), arterial stiffness, and bl

138 Flow-mediated dilation (FMD), arterial stiffness, blood

139 ure of endothelial function, brachial artery flow-mediated dilation (FMD), expressed as both percent

140 l artery measures, including brachial artery flow-mediated dilation (FMD), has not been well establis

141 Arterial stiffness, flow-mediated dilation (FMD), nitroglycerin-mediated dil

142 preoperative vascular function tests (VFTs): flow-mediated dilation (FMD), nitroglycerin-mediated dil

143 At baseline and after 6 wk of intervention, flow-mediated dilation (FMD), soluble vascular adhesion

144 in significant improvements in acute/chronic flow-mediated dilation (FMD), systolic (SBP) and diastol

145 Brachial artery flow-mediated dilation (FMD), urinary 8-isoprostaglandin

146 An acute increase in blood flow triggers flow-mediated dilation (FMD), which is mainly mediated b

147 Flow-mediated dilation (FMD),primary outcome, along with

148 astocytosis using a noninvasive technique of flow-mediated dilation (FMD).

149 ction assessed by reactive hyperemia-induced flow-mediated dilation (FMD).

150 exed by direct assessment of brachial artery flow-mediated dilation (FMD).

151 and vascular function using brachial artery flow-mediated dilation (FMD).

152 al function was evaluated by brachial artery flow-mediated dilation (FMD).

153 onic vessel wall tracking of brachial artery flow-mediated dilation (FMD).

154 opment of atherosclerosis and is assessed by flow-mediated dilation (FMD).

155 systemic macrovascular function by means of flow-mediated dilation (FMD).

156 l artery endothelial function as measured by flow-mediated dilation (FMD).

157 ry endpoints were safety and brachial artery flow-mediated dilation (FMD).

158 id-artery intimal media thickness (cIMT) and flow-mediated dilation (FMD).

159 outcome was endothelial function measured by flow-mediated dilation (FMD).

160 e and after brachial artery occlusion [i.e., flow-mediated dilation (FMD)] and before and after nitro

161 Brachial artery flow-mediated dilation (FMD, endothelium dependent) and

162 n ultrasound images were used to measure the flow-mediated dilation (FMD; endothelium dependent) and

163 Flow-mediated-dilation (FMD) was also performed.

164 ameter of the brachial artery in response to flow-mediated dilation (%FMD).

165 - 30 mmol/day), and conduit (brachial artery flow-mediated dilation [FMD(BA)]) and resistance (forear

166 asured endothelial function (brachial artery flow-mediated dilation [FMD(BA)]) in age-matched late- a

167 ion to brachial artery vasodilator function (flow-mediated dilation [FMD] and reactive hyperemia) ass

168 nction in the systemic arterial circulation (flow-mediated dilation [FMD] in the brachial artery) and

169 Endothelial function (brachial artery flow-mediated dilation [FMD]) was measured at baseline,

170 nd points included change in brachial artery flow-mediated dilation (FMDBA) and aortic pulse-wave vel

171 The primary outcome was the change in flow-mediated dilation from pre- to postintervention.

172 centile, absence of carotid plaque, brachial flow-mediated dilation >5% change, ankle-brachial index

173 t increment (0.623 vs 0.784), while brachial flow-mediated dilation had the least (0.623 vs 0.639).

174 for the CVD risk biomarkers - i.e., brachial flow-mediated dilation, high-frequency heart rate variab

175 ia thickness, ankle-brachial index, brachial flow-mediated dilation, high-sensitivity C-reactive prot

176 Flow-mediated dilation improved from 6.6+/-3.5% to 10.1+

177 Brachial artery flow-mediated dilation improved on all therapies (all P<

178 tion ultrasound to determine brachial artery flow-mediated dilation in 50 pediatric heart transplant

179 olidine carboxylate (OTC) on EDNO-dependent, flow-mediated dilation in a randomized double-blind plac

180 ; nitric oxide synthase inhibitor) abolished flow-mediated dilation in arterioles from subjects witho

181 IR caused a significant reduction in flow-mediated dilation in healthy volunteers (baseline,

182 type 5 cGMP phosphodiesterase inhibitor, on flow-mediated dilation in heart failure is unknown.

183 Flow-mediated dilation in patients with cardiovascular d

184 Heart rate, blood pressure, flow-mediated dilation in the brachial artery, and carot

185 Impaired flow-mediated dilation in vivo correlated with increased

186 3-glucoside supplementation had no effect on flow-mediated dilation, insulin resistance, or other CVD

187 Ultrasound assessment of brachial artery flow-mediated dilation is emerging as a useful clinical

188 Flow-mediated dilation is less variable than PWA.

189 Endothelial function (flow-mediated dilation), liver fat (MRI/magnetic resonan

190 Flow-mediated dilation, low-flow-mediated constriction,

191 HT had significant impairment of flow-mediated dilation (mean vasodilation 5+/-6%; P=0.01

192 nally increased endothelial function (higher flow-mediated dilation: mean 8.2 +/- 3.2% vs. 8.1 +/- 3.

193 Flow-mediated dilation measured by B-ED is robust and pr

194 artery endothelial function was assessed by flow-mediated dilation (n = 25 patients) at baseline and

195 age, 62 years) with measured brachial artery flow-mediated dilation (n=1446) or hyperemic flow veloci

196 The postischemic flow-mediated dilation of brachial artery decreased from

197 and 3 hours after treatment, we assessed (1) flow-mediated dilation of brachial artery; (2) coronary

198 The mechanism involves enhanced, flow-mediated dilation of stenotic epicardial conduit ve

199 ced collateral remodeling, angiogenesis, and flow-mediated dilation of the arterial bed supplying the

200 Flow-mediated dilation of the brachial and femoral arter

201 9 versus 18.6+/-6.7 micromol/L, P=0.546), on flow-mediated dilation of the brachial artery (11.9+/-6.

202 Flow-mediated dilation of the brachial artery (by ultras

203 sted endothelial function in all women using flow-mediated dilation of the brachial artery at 23-25 w

204 d) ascorbic acid treatment on EDNO-dependent flow-mediated dilation of the brachial artery in patient

205 Endothelial function was evaluated by flow-mediated dilation of the brachial artery in vivo an

206 Flow-mediated dilation of the brachial artery was 25% sm

207 Flow-mediated dilation of the brachial artery was measur

208 n patients with HFpEF.; METHODS AND RESULTS: Flow-mediated dilation of the brachial artery, matrix me

209 We assessed systemic (flow-mediated dilation of the brachial artery, pulse-wav

210 consumption improved endothelium- dependent flow-mediated dilation of the brachial artery, whereas c

211 th echocardiography, arterial tonometry, and flow-mediated dilation of the brachial artery.

212 In vivo flow-mediated dilation of the RA is comparable to that o

213 IR reduced flow-mediated dilation of the radial artery at 15 minute

214 No significant changes were seen in either flow-mediated dilation or augmentation index.

215 ween haplotypes (minimum P=0.002) and either flow-mediated dilation or hyperemic flow velocity.

216 low (OR, 1.23 [95% CI, 1.04-1.46]) and lower flow-mediated dilation (OR, 0.80 [95% CI, 0.67-0.96]) du

217 Flow-mediated dilation (p < 0.001) and PWA with salbutam

218 tin 40 mg reduced ROCK activity and improved flow-mediated dilation (P<0.01 for both compared with ba

219 surgery (P=0.05), and lower brachial artery flow-mediated dilation (P=0.007).

220 d HDL), endothelial function [as assessed by flow-mediated dilation, peripheral arterial tonometry/En

221 Biomarkers of vascular function (flow-mediated dilation, plasma total nitrate/nitrite, en

222 (P=0.01) and correlated with improvement in flow-mediated dilation (R(2)=-0.78, P<0.01).

223 soprostaglandin F2alpha (r=0.38; P=0.01) and flow-mediated dilation (r=-0.34; P=0.04).

224 betic patients and was associated with lower flow-mediated dilation (r=-0.541, P=0.02).

225 salsalate was inversely related to baseline flow-mediated dilation (r=-0.77, P<0.01).

226 ction in humans, we measured brachial artery flow-mediated dilation, reactive hyperemia, and serum co

227 I elevation was not considered an event, low flow-mediated dilation remained an independent predictor

228 Flow-mediated dilation remains the most reproducible met

229 gher (0.03 of 1.30 [2.3%]; P < .05), luminal flow-mediated dilation severely blunted (-3.2% of 9.4% [

230 Epicatechin supplementation did not change flow-mediated dilation significantly (1.1% absolute; 95%

231 Endothelial function, which was measured as flow-mediated dilation, significantly improved and was n

232 Flow-mediated dilation studies indicated no meaningful c

233 Selective loss of flow-mediated dilation suggests a role for fibrillin in

234 , applanation tonometry, and brachial artery flow-mediated dilation testing.

235 eloped pre-eclampsia had significantly lower flow-mediated dilation than did women who had normal out

236 se plasma BH4 and had a greater reduction of flow-mediated dilation than OO patients.

237 us +2%) and femoral (+30% versus +3%) artery flow-mediated dilation, the nitric oxide turnover/produc

238 For brachial artery flow-mediated dilation, those in the treadmill group had

239 s vagally mediated modulation of heart rate, flow-mediated dilation to evaluate endothelial function,

240 Secondary outcomes were brachial artery flow-mediated dilation, treadmill walking performance, t

241 Endothelial function was determined by flow-mediated dilation using ultrasound.

242 8.3 (1.4) mg/dl, respectively, and baseline flow-mediated dilation values (SDs) of 6.0% (5.0%) and 4

243 coronary artery calcium was 0.659, brachial flow-mediated dilation was 0.024, ankle-brachial index w

244 er long-term treatment (9.0+/-3.7%), whereas flow-mediated dilation was 8.6+/-4.7% at baseline and re

245 In 19 healthy subjects, flow-mediated dilation was assessed before and after who

246 Flow-mediated dilation was examined by high-resolution v

247 Brachial artery flow-mediated dilation was examined with high-resolution

248 Flow-mediated dilation was highly predictive for CAD wit

249 Flow-mediated dilation was inversely related to arterial

250 Flow-mediated dilation was inversely related to baseline

251 Flow-mediated dilation was linearly proportional to hype

252 n, in isolated pressurized carotid arteries, flow-mediated dilation was markedly reduced in Cav-1 KO

253 Flow-mediated dilation was measured at baseline and 4 h

254 Flow-mediated dilation was measured in vessels pretreate

255 ssociated with exercise systolic BP, whereas flow-mediated dilation was negatively associated (P<0.00

256 Flow-mediated dilation was negatively associated with L5

257 Flow-mediated dilation was reduced at 15 minutes of reco

258 the absolute maximal percent brachial artery flow-mediated dilation was reduced by 0.67%.

259 Flow-mediated dilation was reduced by IR (8.7 +/- 1.1% b

260 Flow-mediated dilation was significantly impaired in pat

261 Flow-mediated dilation was significantly lower in black

262 Preoperative endothelium-dependent flow-mediated dilation was significantly lower in patien

263 Peak flow-mediated dilation was similar, but the duration of

264 EDD (brachial artery flow-mediated dilation) was approximately 50% lower in o

265 achial artery reactivity, using postischemic flow-mediated dilation, was also measured.

266 For flow-mediated dilation, we found no evidence that inflam

267 flow-mediated dilation, and brachial artery flow-mediated dilation were measured at baseline and dur

268 Baseline arterial diameter and percentage of flow-mediated dilation were measured by ultrasound.

269 Carotid intima-media thickness and brachial flow-mediated dilation were not associated with incident

270 Protein expression and flow-mediated dilation were not significantly affected b

271 endothelial assessment using brachial artery flow-mediated dilation were obtained at baseline and at

272 pression of eNOS and phosphorylated eNOS and flow-mediated dilation were significantly lower, whereas

273 ssibility that assessment of brachial artery flow-mediated dilation will be useful in the management

274 The change in brachial artery flow-mediated dilation with salsalate was inversely rela